150399-21-6
150399-21-6
Chemical Structure
Balsalazide sodium hydrate
Synonym(s): Balsalazide disodium dihydrate
- CAS No.: 150399-21-6
- Formula:C17H17N3Na2O8
- Molecular Weight:437.31
IUPAC Name: sodium (E)-3-(4-((3-carboxy-4-oxidophenyl)diazenyl)benzamido)propanoate dihydrate
InChIKey: XDCNKOBSQURQOZ-MVIJUDHYSA-L
SMILES: O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O[Na])=O)=O)C=C2)=CC=C1O[Na].O.O
Biological Activity: Balsalazide sodium hydrate is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Balsalazide sodium hydrate | 99.65% | Balsalazide sodium hydrate is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. [Content Brief]
- [2]. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. [Content Brief]
- [3]. Seema A Patil, et al. Balsalazide disodium for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2008 Apr;2(2):177-84. [Content Brief]
